ClinicalTrials.gg
CompletedNCT01882803DYNAMOUpdated Sep 7, 2023Results posted

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

A Phase 2 interventional study of Duvelisib in Indolent Non-Hodgkin Lymphoma, sponsored by SecuraBio. Completed at 69 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by SecuraBio · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma [FL], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).

Read the detailed description

This was an open-label, single-arm safety and efficacy study of duvelisib administered orally to participants who had been diagnosed with iNHL whose disease was refractory to rituximab and to either chemotherapy or RIT.

Approximately 120 participants received 25 milligrams of duvelisib twice daily over the course of 28-day treatment cycles for up to 13 cycles.

After completing 13 treatment cycles of duvelisib, participants continued to receive additional cycles of duvelisib until disease progression or unacceptable toxicity. However, to receive additional cycles of duvelisib beyond 13 cycles, participants must have had evidence of response (complete response [CR] or partial response [PR]) or stable disease according to the International Working Group criteria by the end of Cycle 13.

02

Conditions studied

  • Indolent Non-Hodgkin Lymphoma

Keywords

  • PI3K Inhibitor
03

In context

Lead sponsor

SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who had been diagnosed with iNHL that had progressed.
  • Participants must have exhibited lack of CR or progressive disease (PR) or progression within 6 months after the last dose of a chemotherapy induction regimen or RIT.
  • Participants must have had rituximab- disease, defined as lack of CR or PR or PD within 6 months of last dose.
  • with a lymph node or tumor mass ≥1.5 centimeters in at least one dimension by computed tomography (CT), positron emission tomography/CT or magnetic resonance imaging.
  • Adequate renal and hepatic function.

Exclusion criteria

Exclusion Criteria:

  • Candidate for potentially curative therapies in the opinion of the investigator.
  • Previous treatment with a PI3K inhibitor or Bruton's tyrosine kinase inhibitor.
  • Prior history of hematopoietic stem cell transplant.
  • Prior chemotherapy, cancer therapy, or other agents within 4 weeks before first dose of study drug.
  • Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype of lymphoma.
  • Symptomatic central nervous system NHL.
  • Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment.
  • Prior, current, or chronic or infection, positive result for hepatitis C virus antibodies, hepatitis B surface antigen, or hepatitis B core antibodies.
  • History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Duvelisib

    Drug: Duvelisib

Interventions

  • Phosphoinositide-3-kinase (PI3K) inhibitor

    Also known as: Copiktra, IPI-145

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR, defined as the total percentage of participants who had a best overall response of either complete response (CR) or partial response (PR), was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma. ORR is reported with a 2-sided 95% exact confidence interval.

    Time frame: Every 8-16 weeks while on treatment with duvelisib for up to 72 months

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as any adverse event that emerged or worsened in the period from the first dose of study treatment to 30 days after the last dose of study treatment. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Every 2-8 weeks for up to 73 months

  2. Duration of Response (DOR)

    DOR, defined as the time from the first documentation of response to either progressive disease (PD) or death due to any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

    Time frame: Every 8-16 weeks for up to 72 months

  3. Progression-free Survival (PFS)

    PFS, defined as the time from the first dose of study treatment to the first documentation of either Investigator-assessed PD or death resulting from any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

    Time frame: Every 8-16 weeks for up to 72 months

  4. Overall Survival (OS)

    OS, defined as the time from the first dose of study treatment to the date of death, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

    Time frame: Every 16 weeks for up to 72 months

  5. Plasma Concentration of Duvelisib and IPI-656

    The serum concentration of duvelisib and its main metabolite, IPI-656, are reported for Day 15 of Cycle 1 (C1D15) and Day 1 of Cycle 2 (C2D1) and Day 1 of Cycle 3 (C3D1). Results are reported in nanograms/milliliter (ng/mL).

    Time frame: Every 4 weeks for 12 weeks (C1D15: predose, 1 and 4 hours post dose; C2D1 and C3D1: anytime during study visit)

  6. Time to Response (TTR)

    TTR, defined as the time from the first dose of study treatment to the first documentation of response, was evaluated by an independent, third-party panel of radiologists and oncologists (Independent Review Committee \[IRC\]) according to the revised IWG Response Criteria for Malignant Lymphoma.

    Time frame: First dose to first documentation of complete or partial response (up to 6 months)

07

Results

Posted Nov 20, 2018

Participant flow

This multicenter, multinational study enrolled participants at 56 medical clinics across 12 countries.

Participant flow — Overall Study
MilestoneDuvelisib
Started129
Received at least 1 dose of study drug129
Completed0
Not completed129
Withdrew: Disease progression1
Withdrew: Withdrawal by subject9
Withdrew: Death68
Withdrew: Physician decision3
Withdrew: Lost to follow-up3
Withdrew: Follow-up completed39
Withdrew: Study terminated by the sponsor6

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR, defined as the total percentage of participants who had a best overall response of either complete response (CR) or partial response (PR), was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma. ORR is reported with a 2-sided 95% exact confidence interval.

Time frame:
Every 8-16 weeks while on treatment with duvelisib for up to 72 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsDuvelisib
Overall Response Rate (ORR)59.7 (50.7 to 68.2)
Statistical analysis
  • Duvelisib · Exact Binomial Test · p = <=0.0001 ('\<=' represents '≤')The p-value was calculated by 1-sided exact binomial test with the null hypothesis that ORR ≤30%.
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as any adverse event that emerged or worsened in the period from the first dose of study treatment to 30 days after the last dose of study treatment. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Every 2-8 weeks for up to 73 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsDuvelisib
Number of Participants With Treatment-emergent Adverse Events (TEAEs)128
SecondaryDuration of Response (DOR)

DOR, defined as the time from the first documentation of response to either progressive disease (PD) or death due to any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

Time frame:
Every 8-16 weeks for up to 72 months
Reported as:
Median · months
Duration of Response (DOR)
monthsDuvelisib
Duration of Response (DOR)10.16 (8.78 to 13.61)
SecondaryProgression-free Survival (PFS)

PFS, defined as the time from the first dose of study treatment to the first documentation of either Investigator-assessed PD or death resulting from any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

Time frame:
Every 8-16 weeks for up to 72 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsDuvelisib
Progression-free Survival (PFS)9.57 (8.35 to 11.70)
SecondaryOverall Survival (OS)

OS, defined as the time from the first dose of study treatment to the date of death, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.

Time frame:
Every 16 weeks for up to 72 months
Reported as:
Median · months
Overall Survival (OS)
monthsDuvelisib
Overall Survival (OS)28.96 (21.37 to 37.02)
SecondaryPlasma Concentration of Duvelisib and IPI-656

The serum concentration of duvelisib and its main metabolite, IPI-656, are reported for Day 15 of Cycle 1 (C1D15) and Day 1 of Cycle 2 (C2D1) and Day 1 of Cycle 3 (C3D1). Results are reported in nanograms/milliliter (ng/mL).

Time frame:
Every 4 weeks for 12 weeks (C1D15: predose, 1 and 4 hours post dose; C2D1 and C3D1: anytime during study visit)
Reported as:
Median · ng/mL
Plasma Concentration of Duvelisib and IPI-656
ng/mLDuvelisibIPI-656
C1D15 Predose414 (19 to 4590)648 (116 to 6010)
C1D15 1 hour post dose1175 (206 to 6820)641 (160 to 5920)
C1D15 4 hours post dose852 (233 to 5170)714 (230 to 6020)
C2D1631 (NA to 4180)704 (NA to 10200)
C3D1696 (NA to 3540)664 (NA to 6850)
SecondaryTime to Response (TTR)

TTR, defined as the time from the first dose of study treatment to the first documentation of response, was evaluated by an independent, third-party panel of radiologists and oncologists (Independent Review Committee \[IRC\]) according to the revised IWG Response Criteria for Malignant Lymphoma.

Time frame:
First dose to first documentation of complete or partial response (up to 6 months)
Reported as:
Median · month
Time to Response (TTR)
monthDuvelisib
Time to Response (TTR)1.87 (1.71 to 3.65)

Adverse events

Collected over 73 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Duvelisib68/129 (52.7%)83/129 (64.3%)122/129 (94.6%)
Most frequent serious events
Showing 10 of 103
Most frequent serious events
EventDuvelisib
DiarrhoeaGastrointestinal disorders10/129
Febrile neutropeniaBlood and lymphatic system disorders9/129
Disease progressionGeneral disorders9/129
PneumoniaInfections and infestations7/129
ColitisGastrointestinal disorders6/129
PancytopeniaBlood and lymphatic system disorders4/129
PyrexiaGeneral disorders4/129
BronchopneumoniaInfections and infestations4/129
Renal failure acuteRenal and urinary disorders4/129
PneumonitisRespiratory, thoracic and mediastinal disorders4/129
Most frequent other events
Showing 10 of 44
Most frequent other events
EventDuvelisib
DiarrhoeaGastrointestinal disorders63/129
NauseaGastrointestinal disorders38/129
NeutropeniaBlood and lymphatic system disorders37/129
FatigueGeneral disorders37/129
AnaemiaBlood and lymphatic system disorders36/129
CoughRespiratory, thoracic and mediastinal disorders35/129
PyrexiaGeneral disorders32/129
ThrombocytopeniaBlood and lymphatic system disorders25/129
VomitingGastrointestinal disorders22/129
Oedema peripheralGeneral disorders22/129

Baseline characteristics

Full Analysis Set (FAS): all participants who received at least 1 dose of duvelisib.

Age, Categorical
Age, Categorical(Participants)Duvelisib
<=18 years0
Between 18 and 65 years64
>=65 years65
Age, Continuous
Age, Continuous(years)Duvelisib
Mean63.6 ± 11.69
Sex: Female, Male
Sex: Female, Male(Participants)Duvelisib
Female41
Male88
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Duvelisib
Hispanic or Latino3
Not Hispanic or Latino118
Unknown or Not Reported8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Duvelisib
American Indian or Alaskan Native1
Asian1
Black or African American6
Native Hawaiian or other Pacific Islander0
White116
Other1
Unknown2
Missing2
Region of Enrollment
Region of Enrollment(participants)Duvelisib
Hungary7
United States46
Czechia9
United Kingdom11
Belarus10
Spain2
Canada9
Belgium2
Italy21
Georgia1
France6
Bulgaria5
08

Study locations

69 sites
  • Los Angeles, California 90095-6984, United States
  • Whittier, California 90603, United States
  • Denver, Colorado 80218, United States
  • Fort Myers, Florida 39916, United States
  • Saint Petersburg, Florida 33705, United States
  • Tallahassee, Florida 32308, United States
  • Atlanta, Georgia 30322, United States
  • Chicago, Illinois 60637, United States
  • Louisville, Kentucky 40207, United States
  • Baltimore, Maryland 21204, United States
  • Baltimore, Maryland 21229, United States
  • Boston, Massachusetts 02215, United States
  • Saint Louis, Missouri 63110, United States
  • Howell, New Jersey 07731, United States
  • Morristown, New Jersey 07962, United States
  • New York, New York 10021, United States
  • Rockville Centre, New York 11510, United States
  • Canton, Ohio 44718, United States
  • Lawton, Oklahoma 73505, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Philadelphia, Pennsylvania 01911, United States
  • Nashville, Tennessee 37203, United States
  • Dallas, Texas 75246, United States
  • Lynchburg, Virginia 24501, United States
  • Lesnoy, Minsk Region 223040, Belarus
  • Brest, 224027, Belarus
  • Minsk, 220013, Belarus
  • Vitebsk, 210603, Belarus
  • Gent, 9000, Belgium
  • Kortrijk, 8500, Belgium
  • Sofia, 1233, Bulgaria
  • Sofia, 1407, Bulgaria
  • Sofia, 1431, Bulgaria
  • Sofia, 1756, Bulgaria
  • Toronto, Ontario M5G 2M9, Canada
  • Gatineau, Quebec J8P7H2, Canada
  • Montreal, Quebec H3T 1E2, Canada
  • Brno, 625-00, Czechia
  • Ostrava-Poruba, 708-52, Czechia
  • Angers Cedex 09, 49933, France
  • Bordeaux, 33076, France
  • Clermont-Ferrand, 63000, France
  • Marseille, 13005, France
  • Pierre Benite, 69495, France
  • Tbilisi, 0186, Georgia
  • Budapest, 1083, Hungary
  • Budapest, 1122, Hungary
  • Debrecen, 4032, Hungary
  • Bologna, 40138, Italy
  • Brescia, 25123, Italy
  • Busto Arsizio, 21052, Italy
  • Genova, 16132, Italy
  • Meldola, 47014, Italy
  • Milano, 20162, Italy
  • Modena, 41124, Italy
  • Orbassano, 10043, Italy
  • Parma, 43100, Italy
  • Ravenna, 48121, Italy
  • Rimini, 47923, Italy
  • Varese, 21100, Italy
  • Barcelona, 08036, Spain
  • Madrid, 28222, Spain
  • Salamanca, 37007, Spain
  • Cardiff, CF 14 4XW, United Kingdom
  • Chelsea, United Kingdom
  • Liverpool, L7 8XP, United Kingdom
  • London, NW1 2PG, United Kingdom
  • London, W1G 6AD, United Kingdom
  • Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, Kelly VM, Shi W, Steelman L, Le N, Weaver DT, Lustgarten S, Wagner-Johnston ND, Zinzani PL. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019 Apr 10;37(11):912-922. doi: 10.1200/JCO.18.00915. Epub 2019 Feb 11. Erratum In: J Clin Oncol. 2019 Jun 1;37(16):1448. doi: 10.1200/JCO.19.00976. PubMed 30742566 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2013 to primary completion in Nov 2020, 89 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2013
First posted
Jun 20, 2013
StartActual
Jun 17, 2013
Primary completionActual
Nov 18, 2020
CompletionActual
Nov 18, 2020
Results delay requested
May 11, 2017
Results first posted
Nov 20, 2018
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01882803
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Jun 20, 2013
Start date
Jun 17, 2013
Primary completion
Nov 18, 2020
Completion
Nov 18, 2020
Results posted
Nov 20, 2018
Last update
Sep 7, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion